List view / Grid view
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
29 January 2016 | By Victoria White
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam...
29 January 2016 | By Victoria White
Halaven is the first and only single agent to demonstrate an overall survival benefit in a Phase III trial in patients with leiomyosarcoma or liposarcoma...
29 January 2016 | By Victoria White
The study demonstrated superior overall survival (OS) in patients receiving Opdivo compared to the control arm...
29 January 2016 | By Victoria White
Zepatier is a once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir...
29 January 2016 | By Victoria White
The expanded label allows for the use of Daklinza (daclatasvir) in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV...
28 January 2016 | By Victoria White
Inovio and GeneOne Life Science are co-developing Inovio’s MERS vaccine (GLS-5300) in partnership with the Walter Reed Army Institute of Research...
28 January 2016 | By Victoria White
The European Commission has approved two new indications for Lilly’s Cyramza (ramucirumab): one in patients with NSCLC and the other in patients with mCRC...
28 January 2016 | By Victoria White
GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline...
28 January 2016 | By Victoria White
This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer...
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
27 January 2016 | By Victoria White
The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide...
27 January 2016 | By Victoria White
Bezlotoxumab is designed to neutralize C. difficile toxin B, a toxin that can damage the gut wall and cause inflammation, leading to C. difficile-associated diarrhoea...
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
